A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Phase 1/2
Terminated
NCT05949632
| Condition | Advanced Solid Tumors |
|---|
| Phase | Phase 1/2 |
|---|
| Sponsor | Incyte Corporation |
|---|
| Status | Terminated |
|---|
| Enrollment | 5 participants |
|---|
| Interventions | INCB099280, axitinib |
|---|
| Start date | Apr 16, 2024 |
|---|
| Completion date | Jun 6, 2025 |
|---|
| Results posted | Jun 4, 2026 |
|---|
Summary
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
up to 3 weeks · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 1 Participants |
|---|
Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
up to approximately 1 year · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 5 Participants |
|---|
Part 1: Number of Participants With TEAEs Leading to a Dosing Modification (Treatment Interruption, Dose Reduction, and Permanent Discontinuation of Either Study Drug)
up to approximately 1 year · Participants
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 5 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 0 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 4 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 3 Participants |
|---|
| INCB099280 400 mg BID Plus Axitinib 5 mg BID | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.